The question arrives honestly. These medicines change appetite, sometimes dramatically, and people whose relationship with eating already feels out of control reasonably wonder what that change means for them. There is a real research literature on the subject, and it is small enough that its size is the first fact worth knowing. Before any of it: binge eating disorder is a diagnosis a clinician makes, this page reports evidence rather than offering help with eating, and a neighbouring subject is a different thing entirely. Late-Night Eating on a GLP-1 covers an ordinary eating pattern, not a disorder, and neither page should be mistaken for the other.
The labels are silent
The words binge and eating disorder appear nowhere in the ten current US labels for this class, checked on November 4, 2026. There is no indication, no warning and no screening instruction anywhere in the labelling. As with every silence in a label, this is not a verdict in either direction; it means the question did not reach the labelling, and the labels are the documents that govern what these medicines are approved for. No medicine in the class is approved for any eating disorder.
Five studies, 182 participants
The evidence base in one sentence: a 2025 systematic review and meta-analysis in the journal Eating and Weight Disorders examined GLP-1 receptor agonists in eating disorders, and it included five studies with 182 participants in total. That number belongs at the front of any account of this research, because 182 people across five studies is a very small base for a clinical question this serious.
What the review found, stated as it reported it: patients receiving GLP-1 agonists had greater weight loss than controls, about 3.81 kg, with reductions in BMI of about 1.48 and waist circumference of about 3.14 cm. Scores on the Binge Eating Scale improved significantly, by about 8.14 points, with a 95 percent confidence interval running from 3.15 to 13.13, though the review reported substantial heterogeneity between studies. The authors concluded that the data are limited, particularly for eating disorders other than binge eating disorder and for long-term effects, and that further comprehensive trials are needed.
Two parts of that deserve a second read. Substantial heterogeneity means the pooled studies did not agree closely with each other, which weakens what a pooled number can tell you. And the authors' conclusion is a request for more research, which is what the people who did the work thought the evidence supported. The numbers, the size of the base and the request for more research belong together; any one of them read alone gives the wrong impression.
What a scale score is, and is not
The Binge Eating Scale is a questionnaire used in research to measure severity. A change in a questionnaire score is a research measurement, not a clinical outcome by itself, and a score moving in a pooled analysis is a different claim from a disorder being treated. This is the same distinction between a surrogate and an outcome taught at How to Read a GLP-1 Study Headline: Relative Risk, Subgroups and Funding, and it does a lot of quiet work in this literature: a questionnaire can improve in a study while the clinical picture, treated by clinicians over time, is a question the study was not designed to answer.
Why the appetite connection needs care
People connect this research to their own experience because appetite on these medicines genuinely changes, and because many report that intrusive thoughts about food quiet down, an experience covered at Food Noise: What It Is and How GLP-1s Change It. The connection is understandable and it is still an inference. The trials behind the review measured specific outcomes in diagnosed populations under study conditions, and an appetite change someone notices day to day does not transfer into evidence about treating a disorder. The one thing this subject must insist on follows from that: eating disorders are treated by clinicians who specialise in them, and medication questions in that context belong inside that care rather than around it.
On logging, carefully
A word on tracking, because this site is about tracking and this subject is the wrong place for a default. The GLP 1 Tracker App logs food, protein, water, fiber and activity, and a free-text note attaches to dose, weight and side effect entries. For someone in treatment for an eating disorder, what to record and whether to record at all is a question for their clinician, whose answer depends on the person and the treatment. Logging is a tool some care teams use and others set aside, and a tool is not a therapy. Anyone in that care should bring the question there first, and treat no app, ours included, as part of the treatment.
Frequently asked questions
Is any GLP-1 approved to treat binge eating disorder?
No. The words binge and eating disorder appear nowhere in the ten current US labels for this class, checked on November 4, 2026. There is no indication, no warning and no screening instruction of any kind, and no medicine in the class is approved for any eating disorder. A diagnosis of binge eating disorder is made by a clinician, and medication questions in that context belong inside that clinical care.
What did the research on GLP-1s and binge eating find?
A 2025 systematic review and meta-analysis in the journal Eating and Weight Disorders pooled five studies with 182 participants in total. GLP-1 groups lost about 3.81 kg more than controls, with BMI reductions of about 1.48 and waist circumference reductions of about 3.14 cm, and Binge Eating Scale scores improved by about 8.14 points. The review reported substantial heterogeneity between studies, and its authors concluded the data are limited and further comprehensive trials are needed.
Does an improved Binge Eating Scale score mean the disorder was treated?
No, and the distinction matters. The Binge Eating Scale is a questionnaire used in research to measure severity, and a pooled change in a questionnaire score is a research measurement, not a clinical outcome by itself. The same review that reported the improvement also reported substantial heterogeneity, meaning the studies did not agree closely with each other, and its authors asked for further trials rather than declaring a treatment. This is the standard difference between a surrogate and an outcome.
Is binge eating disorder the same thing as eating a lot at night?
No. Binge eating disorder is a clinical diagnosis made by a clinician against defined criteria, while eating a lot in the evening is an ordinary pattern many people have for ordinary reasons, and one page on this site covers it as such. Equating the two does a disservice to both: it trivialises a condition that deserves specialist care and it medicalises an eating habit that is not a disorder. Nothing on this site screens for any diagnosis.
Should someone with an eating disorder diagnosis use a tracking app alongside a GLP-1?
That is a question for the clinician treating the eating disorder, and the answer differs from person to person. What to record and whether to record at all belongs inside that care, not around it, and no tracking tool treats an eating disorder. For someone whose care team has asked for dated dose and weight records, the GLP 1 Tracker App keeps food, protein, water, fiber and activity logs on the phone with an optional note on dose, weight and side effect entries, nothing leaving the device.